Literature DB >> 17964629

Enabled interferon signaling evasion in an immune-competent transgenic mouse model of parainfluenza virus 5 infection.

Thomas A Kraus1, Lily Garza, Curt M Horvath.   

Abstract

Parainfluenza virus 5 (PIV5 or SV5) infects several mammalian species but is restricted from efficient replication in mice. In humans, PIV5 evades IFN signaling by targeting STAT1 for proteasomal degradation in a STAT2-dependent reaction. In contrast, cell culture experiments have demonstrated that the divergent murine STAT2 protein fails to support STAT1 targeting. Expression of human STAT2 in mouse cells can overcome the species restriction to enable PIV5-induced STAT1 degradation and subsequent IFN antagonism. Here, we describe a transgenic mouse that ubiquitously expresses human STAT2. PIV5 infection induces STAT1 degradation leading to enhanced virus replication and protein expression in the cells from the transgenic mouse but not from the non-transgenic littermates. Importantly, intranasal inoculation with PIV5 results in increased viral load in the lungs of the transgenic mice compared to wild-type littermates. These transgenic mice provide a small animal model to study the role of innate immune evasion in paramyxovirus pathogenesis.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17964629     DOI: 10.1016/j.virol.2007.10.001

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  14 in total

1.  Mouse STAT2 restricts early dengue virus replication.

Authors:  Joseph Ashour; Juliet Morrison; Maudry Laurent-Rolle; Alan Belicha-Villanueva; Courtney Ray Plumlee; Dabeiba Bernal-Rubio; Katherine L Williams; Eva Harris; Ana Fernandez-Sesma; Christian Schindler; Adolfo García-Sastre
Journal:  Cell Host Microbe       Date:  2010-11-18       Impact factor: 21.023

Review 2.  Paramyxovirus disruption of interferon signal transduction: STATus report.

Authors:  Aparna Ramachandran; Curt M Horvath
Journal:  J Interferon Cytokine Res       Date:  2009-09       Impact factor: 2.607

3.  Measles virus nonstructural C protein modulates viral RNA polymerase activity by interacting with host protein SHCBP1.

Authors:  Minako Ito; Masaharu Iwasaki; Makoto Takeda; Takanori Nakamura; Yusuke Yanagi; Shinji Ohno
Journal:  J Virol       Date:  2013-06-26       Impact factor: 5.103

Review 4.  Paramyxovirus activation and inhibition of innate immune responses.

Authors:  Griffith D Parks; Martha A Alexander-Miller
Journal:  J Mol Biol       Date:  2013-09-20       Impact factor: 5.469

5.  Measles virus V protein inhibits NLRP3 inflammasome-mediated interleukin-1β secretion.

Authors:  Noritaka Komune; Takeshi Ichinohe; Minako Ito; Yusuke Yanagi
Journal:  J Virol       Date:  2011-10-12       Impact factor: 5.103

6.  Human metapneumovirus establishes persistent infection in the lungs of mice and is reactivated by glucocorticoid treatment.

Authors:  Yuru Liu; Debra L Haas; Spencer Poore; Sanjin Isakovic; Michelle Gahan; Suresh Mahalingam; Zhen F Fu; Ralph A Tripp
Journal:  J Virol       Date:  2009-04-08       Impact factor: 5.103

7.  A point mutation, E95D, in the mumps virus V protein disengages STAT3 targeting from STAT1 targeting.

Authors:  Mamta Puri; Ken Lemon; W Paul Duprex; Bertus K Rima; Curt M Horvath
Journal:  J Virol       Date:  2009-04-22       Impact factor: 5.103

8.  Reovirus mu2 protein inhibits interferon signaling through a novel mechanism involving nuclear accumulation of interferon regulatory factor 9.

Authors:  Jennifer Zurney; Takeshi Kobayashi; Geoffrey H Holm; Terence S Dermody; Barbara Sherry
Journal:  J Virol       Date:  2008-12-24       Impact factor: 5.103

Review 9.  STAT2: A shape-shifting anti-viral super STAT.

Authors:  Fatema Z Chowdhury; J David Farrar
Journal:  JAKSTAT       Date:  2013-01-01

10.  The V protein of Tioman virus is incapable of blocking type I interferon signaling in human cells.

Authors:  Grégory Caignard; Marianne Lucas-Hourani; Kevin P Dhondt; Jean-Louis Labernardière; Thierry Petit; Yves Jacob; Branka Horvat; Frédéric Tangy; Pierre-Olivier Vidalain
Journal:  PLoS One       Date:  2013-01-14       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.